TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive In Brief: DeVita wins $150,000 Pezcoller Prize; BreastPac To “Storm” Capitol On Bastille Day For More $$ July 8, 1988
